FULC Fulcrum Therapeutics Forecast, Technical & Fundamental Analysis
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases... Show more
FULC is expected to report earnings to fall 10.68% to -22 cents per share on August 05
Q2'26
Est.
$-0.22
Q1'26
Beat
by $0.05
Q4'25
Est.
$-0.31
Q3'25
Missed
by $0.02
Q2'25
Beat
by $0.01
The last earnings report on April 27 showed earnings per share of -25 cents, beating the estimate of -30 cents. With 323.16K shares outstanding, the current market capitalization sits at 248.88M.
A.I. Advisor
published General Information
General Information
a clinical-stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies.
A.I.dvisor indicates that over the last year, FULC has been loosely correlated with HRTX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then HRTX could also see price increases.
FULC's RSI Indicator climbs out of oversold territory
The RSI Oscillator for FULC moved out of oversold territory on June 18, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In of the 35 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 23, 2026. You may want to consider a long position or call options on FULC as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for FULC just turned positive on June 18, 2026. Looking at past instances where FULC's MACD turned positive, the stock continued to rise in of 33 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FULC advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .
FULC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FULC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.747) is normal, around the industry mean (19.146). P/E Ratio (0.000) is within average values for comparable stocks, (37.848). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.511). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (6.064) is also within normal values, averaging (392.866).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. FULC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FULC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
